Interviews

Arjun V. Balar, MD, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.

Hussein A. Tawbi, MD, PhD, discusses why melanoma responds so well to immunotherapy.

Susan M. O’Brien, MD, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia.

Ghassan Abou-Alfa, MD, discusses the approved agents available for the treatment of hepatocellular carcinoma. Compared to 2007 when there was only 1 agent available, sorafenib, there is now a great number of options for these patients.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.

Michael J. Overman, MD, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer.

Sarah Holstein, MD, PhD, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma. 

Amol K. Narang, MD, discusses the improvement in systemic therapy for treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.

Susana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.

Eric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.

Steven J. Katz, MD, MPH, discusses the benefits and challenges with genetic testing in patients with breast cancer.

Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.

Srdan Verstovsek, MD, PhD, discusses how to control symptoms while using hypomethylating agents in patients with myelofibrosis.

Thomas Powles, MD, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.

Shannon N. Westin, MD, MPH, discusses resistance seen with PARP inhibitors in ovarian cancer and how this resistance can be overcome.

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.

Lori J. Wirth, MD, discusses the role of lenvatinib in the treatment landscape of differentiated thyroid cancer and how this might evolve in the future.

Simon Rule, MD, PhD, shares his treatment considerations for select patients with mantle cell lymphoma.

Ann-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.

Sarah K. Tasian, MD, discusses what she finds most interesting about Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia.

Julie M. Vose, MD, MBA, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.

Cathy Eng, MD, discusses how the PRODIGE 7 trial, though negative, provided valuable evidence to the field for treatment of patients with metastatic colorectal cancer with peritoneal carcinomatosis.

Paolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.

Daniel A. Pollyea, MD, MS, discusses how far the field of acute myeloid leukemia has come in the last 1 to 2 years.

Danielle Brander, MD, discusses the current treatment landscape in the frontline setting for patients with chronic lymphocytic leukemia.

Krishnansu S. Tewari, MD, discusses the excitement around immunotherapy in cervical cancer. 

Eric Smith, MD, PhD, discusses challenges with CAR T-cell therapy as a treatment option for multiple myeloma. While studies have shown CD19 CAR T cells and BCMA CAR T cells have durable responses in this patient population, patients still relapse over time.

Hassane M. Zarour, MD, discusses the addition of antibiotics to immunotherapy treatment in patients with melanoma. 

Riccardo Lencioni, MD, discusses how to successfully integrate Liver Imaging Reporting and Data Systems their clinical practice.<br /> &nbsp;

Masatoshi Kudo, MD, PhD, discusses the potential for systemic therapy in the adjuvant setting of hepatocellular carcinoma. While current trials are investigating this therapy in advanced stage HCC, Kudo believes it could benefit patients following a surgery resecting an aberration.